Biotech · Private company
Verismo Therapeutics
Track this companyFree. Adds Verismo Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials43 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CARPhase 1 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- SynKIR-310Phase 1 · B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- SynKIR-110CancerClinicalTrials.gov · fetched Nov 12, 2026
- SynKIR-310CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell ProductENROLLING_BY_INVITATION · started Jan 27, 2025ClinicalTrials.gov NCT06701201 · fetched Nov 12, 2026
- SynKIR-310 for Relapsed/Refractory B-NHLPHASE1 · RECRUITING · started Nov 1, 2024ClinicalTrials.gov NCT06544265 · fetched Nov 12, 2026
- Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer StudiesWITHDRAWN · started Nov 15, 2023ClinicalTrials.gov NCT06377202 · fetched Nov 12, 2026
- SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or MesotheliomaPHASE1 · RECRUITING · started Mar 30, 2023ClinicalTrials.gov NCT05568680 · fetched Nov 12, 2026